Court Opinion

ID: 9948050
Source: CourtListenerOpinion
Date Created: 2024-03-06 15:01:00.604005+00
Date Added: 2024-06-11T14:29:01.527967
License: Public Domain

Case: 23-2218      Document: 53           Page: 1       Filed: 03/06/2024

            NOTE: This order is nonprecedential.

   United States Court of Appeals
       for the Federal Circuit
                 ______________________

    In Re ENTRESTO (SACUBITRIL/VALSARTAN)
           -------------------------------------------------

 NOVARTIS PHARMACEUTICALS CORPORATION,
             Plaintiff-Appellant

                                    v.

         TORRENT PHARMA INC., TORRENT
            PHARMACEUTICALS LTD.
               Defendants-Appellees

             -------------------------------------------------

 NOVARTIS PHARMACEUTICALS CORPORATION,
             Plaintiff-Appellant

                                    v.

      ALEMBIC PHARMACEUTICALS LIMITED,
        ALEMBIC PHARMACEUTICALS INC.,
                  Defendants

             -------------------------------------------------

 NOVARTIS PHARMACEUTICALS CORPORATION,
             Plaintiff-Appellant

                                    v.
Case: 23-2218     Document: 53           Page: 2       Filed: 03/06/2024

 2                      IN RE ENTRESTO (SACUBITRIL/VALSARTAN)

   HETERO USA, INC., HETERO LABS LIMITED,
     HETERO LABS LIMITED UNIT-III, MSN
 PHARMACEUTICALS, INC., MSN LABORATORIES
  PRIVATE LTD., MSN LIFE SCIENCES PRIVATE
                     LTD.,
             Defendants-Appellees
            ______________________

       2023-2218, 2023-2219, 2023-2220, 2023-2221
                ______________________

     Appeals from the United States District Court for the
 District of Delaware in Nos. 1:19-cv-01979-RGA, 1:19-cv-
 02021-RGA, 1:19-cv-02053-RGA, and 1:20-md-02930-RGA,
 Judge Richard G. Andrews.
            -------------------------------------------------

 NOVARTIS PHARMACEUTICALS CORPORATION,
             Plaintiff-Appellant

                                   v.

         MYLAN PHARMACEUTICALS INC.,
                Defendant-Appellee
              ______________________

                         2023-2260
                   ______________________

    Appeal from the United States District Court for the
 Northern District of West Virginia in No. 1:19-cv-00201-
 TSK, Chief Judge Thomas S. Kleeh.
                 ______________________

                            ORDER
    Novartis Pharmaceuticals Corporation and Mylan
 Pharmaceuticals Inc. submit a joint stipulation to dismiss
Case: 23-2218    Document: 53     Page: 3    Filed: 03/06/2024

 IN RE ENTRESTO (SACUBITRIL/VALSARTAN)                     3

 Appeal No. 2023-2260 pursuant to Rule 42(b)(1) of the Fed-
 eral Rules of Appellate Procedure, agreeing that each bear
 its own costs with respect to Appeal No. 2023-2260.
    Upon consideration thereof,
    IT IS ORDERED THAT:
     (1) Appeal No. 2023-2260 is deconsolidated from Ap-
 peal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-
 2221, and Appeal No. 2023-2260 is dismissed. Each side
 shall bear its own costs regarding Appeal No. 2023-2260.
    (2) The stay in Appeal Nos. 2023-2218, 2023-2219,
 2023-2220, and 2023-2221 is lifted.
     (3) The Clerk of Court shall transmit a copy of this or-
 der to the merits panel assigned to Appeal Nos. 2023-2218,
 2023-2219, 2023-2220, and 2023-2221.
                                              FOR THE COURT

 March 6, 2024
     Date

 ISSUED AS A MANDATE (as to Appeal No. 2023-2260
 only): March 6, 2024